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1. Activity of wild-type enzymes 
 
Figure S1. LCMS traces at 330 nm of reactions with 4-nitroindole and 1 equivalent of serine, using (a) PfTrpB and 
(b) TmTrpB, with (c) Pf2A6 for comparison. See Section 8.7 for reaction conditions.  
2. Effect of loading of Pf2B9 and equivalence of Ser on production of 4-nitrotryptophan 
 
Figure S2. Production of 4-nitrotryptophan under different conditions (see Section 8.7). (a) HPLC yield with 0.02, 
0.1, and 0.2 mol % of Pf2B9 (1 equiv of Ser). (b) HPLC yield with 1, 5, and 10 equivalents of Ser (0.1 mol % of 
Pf2B9). 
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3. Consumption of serine in reaction with 4-nitroindole 
Reactions with 4-nitroindole and 1 equiv of serine were run according to the conditions in Section 9.7. After 12 
hours, the reactions were cooled to room temperature, and then treated with 1.5 equiv of benzoic anhydride in 100 
µL of CH3CN. The reactions were shaken at room temperature. After 1 hour, the reactions were diluted with 1:1 
CH3CN/1 M aq. HCl (800 µL), and then subjected to centrifugation at 20,000×g for 10 minutes at 4 °C. The 
supernatant was analyzed by LCMS according to the method in Section 8.7 (Figure S3).  
 
Figure S3. LCMS traces at 254 nm of (a) control mixture without enzyme and (b) reaction with Pf2B9. The serine 
benzamide peak was identified based on the mass ([M+H]+ = 210). 
4. Formation of nitroisotryptophan side product  
 
Figure S4. LCMS traces at 330 nm of reactions with 4-nitroindole and 10 equiv of serine, using (a) Pf2B9 and (b) 
Pf2B9 L161V. Reaction conditions analogous to those in Section 8.7. We assigned the side product as the N-
alkylation product because it has the same mass as 4-nitroTrp, it absorbs strongly at 330 nm, and we have obtained 
and characterized N-alkylated products from reactions with TrpB in the past (e.g., Table 3, entry 11). 
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5. Results of site-saturation mutagenesis libraries 
 
 
Figure S5. Site-saturation of Pf2A6 at G104 for production of 4-nitrotryptophan. Product formation was measured 
on a UV-vis plate reader (see Sections 8.2 and 8.6). 
 
 
 
Figure S6. Site-saturation of Pf2B9 at L161, I165, V187, and Y301 for production of 6-nitrotryptophan. Product 
formation was measured by HPLC (see Sections 8.2 and 8.6). 
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6. Effect of catalyst loading on production of 4-nitro and 5-nitrotryptophan 
 
Figure S7. Production of 4-nitrotryptophan by Pf2A6 according to HPLC (see Section 8.8). Solid line indicates 
HPLC yield and dashed line indicates the corresponding number of turnovers. 
 
 
Figure S8. Production of 5-nitrotryptophan by Tm2F3 I184F according to HPLC (see Section 8.8). Solid line 
indicates HPLC yield and dashed line indicates the corresponding number of turnovers. 
7. UV-Vis spectra of advanced variants with Ser 
   
Figure S9. UV-vis spectra with 20 µM enzyme in potassium phosphate buffer (200 mM, pH 8) at 75 °C before 
(dashed lines) and after (solid lines) addition of Ser (20 mM final concentration). Peak at ~ 350 nm corresponds to 
the amino-acrylate intermediate (see Section 8.10). 
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8. Procedures for enzyme expression and characterization  
8.1 Cloning, expression, and purification of TrpB variants 
The genes encoding Pf2B91 and TmTrpB2 (UNIPROT ID P50909) were previously cloned into pET22(b)+ with a 
C-terminal His-tag. Protein expression of the variants was carried out in Escherichia coli BL21 E. cloni Express 
cells (Lucigen) by inoculating 5 mL of Lysogeny Broth containing 100 µg/mL ampicillin (LBamp) with a single 
colony and incubating this pre-culture overnight at 37 °C and 230 rpm. The overnight cultures were used to 
inoculate 500 mL of Terrific Broth containing 100 µg/mL ampicillin (TBamp). The expression cultures were shaken 
at 37 °C and 230 rpm for ~3 h, at which point the OD600 was 0.6–0.8. The cultures were then chilled on ice for >30 
min and then induced with by the addition of 1 M aq. isopropyl β-D-thiogalactopyranoside (IPTG, 500 µL, final 
concentration of 1 mM). Expression of the homologs took place at 230 rpm and 20 °C for another 20 h. The cultures 
were subjected to centrifugation at 5,000×g and 4 °C for 5 minutes. The cell pellets were decanted, then frozen and 
stored at –30 °C until further use. 
For protein purification, cells were thawed, then re-suspended in potassium phosphate buffer (25 mM, pH 8) that 
contained 20 mM imidazole, 100 mM NaCl, 200 µM PLP, 1 mg/mL of hen egg white lysozyme (HEWL, Sigma 
Aldrich), and 0.1 mg/mL of bovine pancreas DNase I. BugBuster (Novagen) was added, then the mixture was 
vortexed to suspend the pellet. The suspension was shaken at 37 °C and 230 rpm for 15 min, then subjected to 
centrifugation at 5000×g and 4 °C for 10 minutes. Without decanting, the cell lysate was immersed in a water bath at 
75 °C. After 30 minutes, the suspension was subjected to another centrifugation step (15,000×g and 4 °C for 15 
minutes). The supernatant was purified using a 1-mL histrap HP column with an AKTA purifier FPLC system (GE 
Healthcare) and a linear gradient from buffer A (25 mM potassium phosphate, 20 mM imidazole, 100 mM NaCl, pH 
8) to buffer B (25 mM potassium phosphate, 500 mM imidazole, 100 mM NaCl, pH 8) over 10 volumes. Proteins 
eluted at approximately 140 mM imidazole. Purified proteins were dialyzed into potassium phosphate buffer (50 
mM, pH 8), then flash-frozen in liquid N2 and stored at –80 °C until further use. Protein concentrations were 
determined via the Bradford assay (Bio-Rad). 
 
8.2 Construction of site-saturation mutagenesis libraries 
PCR was conducted using Phusion polymerase (New England Biolabs) according to the standard protocol. For the 
given site of mutagenesis, three primers were designed containing codons NDT (encoding for Ile, Asn, Ser, Gly, 
Asp, Val, Arg, His, Leu, Phe, Tyr, and Cys), VHG (encoding for Met, Thr, Lys, Glu, Ala, Val, Gln, Pro, and Leu), 
and TGG (Trp), respectively, thereby including all 20 natural amino acids. These three primers were mixed in a ratio 
12:9:1 according to the previously described protocol.3 Then, the plasmid was constructed by site-directed 
mutagenesis by overlap extension (SOE) PCR4 using a plasmid that contained the parent gene in the pET22(b)+ 
vector as template. The linear plasmid was digested with DpnI, purified by preparative agarose gel, then cyclized via 
the Gibson method.5  
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8.3 Construction of random recombination libraries 
These libraries were constructed in an analogous manner to the site-saturation libraries, using primers that coded 
for both the native residue and the mutation. The mutant genes were first constructed as fragments, using flanking 
primers that corresponded to the NdeI and XhoI restriction sites on pET22(b)+ (see Section 7.4). The fragments were 
purified by preparative agarose gel, then assembled into a contiguous gene using flanking primers that corresponded 
to the NdeI and XhoI sites of the pET22(b)+ vector. After a final purification by agarose gel, the assembled gene was 
cloned into an empty pET22(b)+ vector between restriction sites NdeI and XhoI using the Gibson method.5 
To improve production of 5-nitrotryptophan, recombination was performed in three stages. First, the mutations 
M18V, P19G, I69V, K96L, T292S, and H381A were randomly recombined in the parent TmTrpB M145T N167D. 
The best variant from this library added the mutations P19G, I69V, K96L, and T292S. This served as the parent for 
the second round, in which the mutations P140L, M145T, N167D, and L213P were randomly recombined. The best 
variant from this library (Tm2F3) added the mutations P140L and L213P, retained the mutation N167D, and 
reverted the mutation M145T to the native residue (M). This served as the parent for the third round, in which the 
mutations E105G, I185F, and V187A were randomly recombined. The best variant from this library added the 
mutation I184F. 
To improve production of 6-nitrotryptophan, recombination was performed in two stages. First, the mutations 
M139L, N166D, and L212P were randomly recombined in the parent Pf2B9 I165F Y301H. The best variant from 
this library (Pf0A9) added mutations M139L and N166D. This served as the parent for the second round, in which 
the mutations E104G, I183F, and V186A were randomly recombined. The best variant from this library added the 
mutation E104G. 
 
8.4 Construction of random mutagenesis libraries 
Random mutagenesis was achieved with error-prone PCR using Taq polymerase (New England Biolabs): 
Reagents mixed in a PCR tube Thermocycler program 
Taq buffer (10×) 10 µL 95 °C 40 s 
dNTP mix (200 µM) 2 µL 95 °C 30 s 
forward primera (100 µM) 2 µL 55 °C 30 s 
reverse primerb (100 µM) 2 µL 68 °C 80 s 
template DNA 1 µL 68 °C 5 min 
MnCl2 (1 mM) 20/30/40 µL 10 °C ∞ 
Taq DNA Polymerase (added last) 0.5 µL   
H2O Add to 100 µL total volume   
aGAAATAATTTTGTTTAACTTTAAG, corresponding to the NdeI restriction site of the pET22(b)+ vector. 
bGCCGGATCTCAGTGGTGGTGGT, corresponding to the XhoI restriction site of the pET22(b)+ vector. 
 
The PCR product was purified by preparative agarose gel, then cloned into an empty pET22(b)+ vector between 
restriction sites of NdeI and XhoI using the Gibson method.5 Libraries generated with 200, 300, and 400 µM MnCl2 
were tested (one 96-well plate, each) to determine which library gave the optimal balance of high diversity and low 
rate of inactivation. The chosen library was then tested further (see below). 
 
 
30 cycles 
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8.5 Transformation of BL21 E. coli cells 
In preparation, SOC medium, 50 µL aliquots of electrocompetent BL21 E. coli cells, and electroporation cuvettes 
were chilled in ice. The plasmid (1 µL) was added to the cells, which were then transferred to a sterile 
electroporation cuvette. An electric potential was applied with a Gene Pulser Xcell (2.5 kV, 25 µF, 200 Ω). Then, 
SOC medium (750 µL) was immediately added and the cuvette was shaken at 37 °C and 230 rpm. After 45 min, 
aliquots of cell suspension were plated onto LBamp agar plates. The plates were incubated overnight at 37 °C, then 
stored at 4°C until further use. 
 
8.6 Library expression and screening 
BL21 E. cloni Express cells carrying parent and variant plasmids were grown in 96-well deep-well plates (300 
µL/well TBamp) at 37 °C and 80% humidity. After shaking at 250 rpm overnight, 20 µL of the overnight cultures 
were transferred to new deep-well plates containing 630 µL/well TBamp, which were allowed to grow at 37 °C and 
80% humidity. After shaking at 250 rpm for 3 h, the plates were chilled on ice for 30 min, then induced by the 
addition of IPTG in TBamp (1 mM final concentration). The cultures were shaken at 250 rpm and 20 °C. After 20 
hours, the cultures were subjected to centrifugation at 4,000×g for 10 min. The cell pellets were frozen at –30 °C for 
a minimum of 2 hours. For screening, cells were thawed at room temperature and then subjected to lysis by the 
addition of 400 µL/well of potassium phosphate buffer (50 mM, pH 8.0), with 1 mg/mL HEWL, 0.1 mg/mL DNase 
I, 40 µM PLP, and 2 mM MgCl2. The plates were incubated for 1 h at 37 °C, then transferred to a water bath 
equilibrated to 75 °C. After 30 min, the plates were chilled in ice, then subjected to centrifugation at 5,000×g and 
4°C for 20 min.   
The reactions were performed in 96-well deep-well plates. In general, each well was charged with the nitroindole 
substrate as a solution in DMSO (10 µL/well). Then, a solution of Ser in potassium phosphate buffer (200 mM, pH 
8.0) was added. Finally, the enzymes were added as heat-treated lysate, such that the total volume in the wells was 
200 µL. All libraries were screened with 2 µmol of nitroindole and 2 µmol of Ser, except for the first random-
mutagenesis library, which used 0.2 µmol 4-nitroindole and 2 µmol of Ser. The volume of heat-treated lysate was 
decreased in each successive round of evolution (80 µL to 20 µL), in order to apply greater selective pressure. 
The plates were sealed with Teflon sealing mats, then immersed in a water bath equilibrated to 75 °C. After ~12 
hours, the plates were chilled in ice and subjected to brief centrifugation (5,000×g, 2 min) to settle the reaction 
contents to the bottom of the wells. Each well was charged with 700 µL of ethyl acetate and 500 µL of aq. 1 M HCl. 
The plates were again sealed with Teflon sealing mats, then shaken vigorously to dissolve all precipitates and 
partition the product and substrate between the aqueous and organic phases, respectively. The plates were again 
subjected to centrifugation (5,000×g, 2 min), then 200 µL of the aqueous phase were transferred to 96-well UV-vis 
assay plates. The activity of each well was determined by measuring the absorption at a given wavelength; the 
wavelength was determined by scanning one of the parent controls from 390 to 500 nm and choosing the 
wavelength at which the absorption was ~0.5. 
For smaller libraries, such as for site-saturation mutagenesis, the reactions could also be analyzed by HPLC. In 
this case, the reactions were diluted with 300 µL of 83% acetonitrile/water (for 4-nitroindole reactions, 1 M aq. HCl 
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was used in place of water). The plates were subjected to centrifugation at 5,000×g and 4 °C for 10 minutes, then the 
supernatants were transferred to a fresh assay plate. Each well was analyzed with a C-18 silica column (4.6 × 50 
mm) using acetonitrile/water (0.1% acetic acid by volume): 5% to 95% acetonitrile over 2 minutes, 95% for 1 min; 1 
mL/min. The yield was approximated by comparing the integrations of the nitrotryptophan signal to the nitroindole 
signal at 330 nm (no reference wavelength).  
All hits were validated using the procedure in Section 8.7. 
 
8.7 Small-scale reactions with heat-treated lysate 
 The enzyme was expressed as a 5-mL culture in TBamp according to the procedure in Section 8.1. The cell pellet 
was suspended in 400 µL potassium phosphate buffer (50 mM, pH 8) that contained 1 mg/mL HEWL, 0.1 mg/mL 
DNase I, and 200 µM PLP. BugBuster was added, then the suspension was shaken at 37 °C and 230 rpm. After 15 
minutes, the suspension was chilled in ice, then subjected to centrifugation at 5,000×g and 4 °C (10 minutes). The 
supernatant was transferred to a 1.5-mL Eppendorf tube, then heated to 75 °C. After 30 minutes, the suspensions 
were chilled in ice, then subjected to centrifugation at 20,000×g and 4 °C (10 minutes). The heat-treated lysate was 
used directly in the biocatalytic reactions. 
A 2-mL HPLC vial was charged with nitroindole as a 200-mM solution in DMSO (10 µL, 2 µmol nitroindole). 
Next, Ser (2 µmol) was added as a solution in 180 µL of potassium phosphate buffer (200 mM, pH 8). Finally, 10 
µL of heat-treated lysate was added, then the reaction was heated to 75 °C. After 12 hours, the reaction was chilled 
in ice, then diluted with 800 µL of 1:1 CH3CN/1 M aq. HCl. The reaction mixture was subjected to centrifugation at 
20,000×g and 4 °C (10 minutes), then the supernatant was analyzed by HPLC with a C-18 silica column (1.8 µm, 
2.1 × 50 mm) using acetonitrile/water (0.1% acetic acid by volume): 5% to 95% acetonitrile over 4 min; 1 mL/min. 
For 4-nitrotryptophan, the HPLC yield was determined using the method described in Section 8.9. For the other 
nitrotryptophans, the HPLC yield was estimated by comparing the integrations of the product and substrate peaks at 
330 nm (no reference wavelength). 
 
Results of Figure 4 
  HPLC Yield of 4-nitroTrp     
Variant Replicate 1 Replicate 2 Average Deviation 
Pf2B9 17.9% 18.4% 18.1% 0.2% 
Pf2B9 L161V 25.3% 24.9% 25.1% 0.2% 
Pf2B9 M139L L161V L212P 48.7% 50.1% 49.4% 0.7% 
Pf2B9 M139L N166D L212P (Pf5G8) 61.2% 59.6% 60.4% 0.8% 
Pf5G8 I183F 69.2% 69.3% 69.2% 0.05% 
Pf5G8 V186A 70.5% 70.6% 70.5% 0.02% 
Pf5G8 E104G 86.3% 86.4% 86.3% 0.05% 
Pf5G8 E104G I183F V186A 90.2% 91.9% 91.1% 0.9% 
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Results of Table 1 
  HPLC Yield of 5-nitroTrp     
Variant Replicate 1 Replicate 2 Average Deviation 
Pf2B9 7.4% 7.5% 7.5% 0.04% 
Pf5G8 69.3% 58.1% 63.7% 6% 
Pf2A6 3.5% 6.3% 4.9% 1.4% 
Tm2F3 75.9% 75.6 75.7% 0.14% 
Tm2F43 I184F 85.3% 86.1% 85.7% 0.4% 
 
  HPLC Yield of 6-nitroTrp     
Variant Replicate 1 Replicate 2 Average Deviation 
Pf2B9 16.9% 17.1% 17.0% 0.09% 
Pf5G8 65.6% 63.2% 64.4% 1.2% 
Pf2A6 22.4% 30.4% 26.4% 4% 
Pf2B9 I165F Y301H 65.8% 65.6% 65.7% 0.10% 
Pf0A9 87.4% 85.4% 86.4% 1.0% 
Pf0A9 E104G 91.6% 90.5% 91.1% 0.6% 
 
  HPLC Yield of 7-nitroTrp     
Variant Replicate 1 Replicate 2 Average Deviation 
Pf2B9 29.2% 29.5% 29.4% 0.15% 
Pf5G8 59.6% 67.9% 63.8% 4% 
Pf2A6 >99% >99% >99% – 
 
8.8 Small-scale reactions with purified protein 
A 2-mL HPLC vial was charged with nitroindole as a 200-mM solution in DMSO (10 µL, 2 µmol nitroindole). 
Next, Ser (2 µmol) and PLP (5 equiv relative to enzyme) was added as a solution in 182 µL of potassium phosphate 
buffer (200 mM, pH 8). Finally, 8 µL of purified protein solution was added (concentration was adjusted depending 
on the desired catalyst loading). The reactions were run and analyzed according to the procedure in Section 8.7. 
 
8.9 Calibration for measuring HPLC yield of 4-nitrotryptophan 
Using an authentic standard of 4-nitrotryptophan, mixtures were prepared that contained 4-nitroindole and 4-
nitrotryptophan in different ratios (9:1, 3:1, 1:1, 1:3, and 1:9). Each mixture was prepared in duplicate, then all were 
analyzed by HPLC using the method in Section 8.7. The ratios of the product and substrate peaks at 254 nm 
(reference 360 nm, bandwidth 100 nm) and 330 nm (no reference wavelength) were correlated to the actual ratios by 
a linear relationship. 
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8.10 Turnover frequency of 4-nitrotryptophan production 
Using the procedure in Section 8.8, reactions with 0.02 mol % of enzyme were run for 1 hour. The HPLC yield of 
4-nitrotryptophan was then determined by HPLC using the calibration in Section 8.9. Three replicates were 
performed of each experiment. 
Enzyme 
 Turnover frequency of 4-nitroTrp (min–1) 
#1 #2 #3 Average Std. deviation 
Pf2B9 1.34 1.16 1.26 1.25 0.07 
Pf5G8 1.9 1.9 1.6 1.8 0.12 
Pf5G8 E104G 3.3 3.4 3.8 3.5 0.2 
Pf2A6 6.8 6.9 7.4 7.0 0.3 
 
8.11 Turnover frequency of Ser deamination 
The sample holder of a UV1800 spectrophotometer (Shimadzu) was heated to 75 °C. For the reactions, enzyme 
and Ser in potassium phosphate buffer (200 mM, pH 8) were added to a quartz cuvette (1 cm path length), such that 
the total volume was 500 µL, and the final concentrations were 20 µM enzyme and 20 mM Ser. The potassium 
phosphate buffer was added first, then the cuvette was placed in the sample holder at 75 °C for at least 3 minutes, 
after which the baseline was measured (300 to 550 nm). Next, the enzyme was added, then the sample was again 
equilibrated to 75 °C for 3 minutes. After recording the UV-vis absorption spectrum (300 to 550 nm), Ser was 
added, then the absorption spectrum (300 to 550 nm) was measured every minute for 30 minutes. The change in 
absorption at 320 nm was correlated with the production of pyruvate using the extinction coefficient ε = 20 M–1cm–1. 
Three replicates of each measurement were performed. 
Enzyme 
Turnover frequency of Ser deamination (min–1) 
#1 #2 #3 Average Std. deviation 
PfTrpB 25.2 25.1 24.5 25.0 0.3 
Pf2B9 11.8 11.9 13.0 12.2 0.5 
Pf5G8 2.2 1.7 2.2 2.0 0.2 
Pf5G8 E104G 0.7 1.0 0.8 0.9 0.12 
Pf2A6 1.5 1.3 1.3 1.4 0.10 
 
8.12 Turnover frequency of Trp production 
Reactions of indole and serine were performed analogously to the procedure in Section 8.10 with the following 
modifications: 0.01 mol % of enzyme was used, the reactions were run for 15 minutes, and the HPLC yield was 
approximated by comparing integrations of the Trp peak and the indole peak at the isosbestic point (277 nm). The 
kcat of Trp production for wild-type PfTrpB has been reported previously.6 
Enzyme 
Turnover frequency of Trp production (min–1) 
#1 #2 #3 Average Std. deviation 
Pf2B9 61.1 60.7 61.0 60.9 0.16 
Pf5G8 10.2 10.3 9.2 9.9 0.5 
Pf5G8 E104G 7.12 7.04 6.94 7.03 0.07 
Pf2A6 18.1 17.3 17.4 17.6 0.3 
 
 
 
 S-13 
8.13 Construction of homology with amino-acrylate and 4-nitroindole 
A structure of TrpS from S. enterica has been reported (PDB ID: 4HPX), in which the β-subunit (SeTrpB) is in 
the closed state and contains benzimidazole and the Ser-derived amino-acrylate in the active site.7 This structure 
served as a template for a homology model of wild-type TrpB from P. furiosus (PfTrpB, 59% sequence identity), 
which was constructed using the Swiss-Model program.8-11 The homology model of PfTrpB was aligned with the 
authentic structure of SeTrpB using PyMol, which allowed the amino-acrylate and benzimidazole to be mapped 
directly into the homology model. Finally, the benzimidazole was replaced with a simulated structure of 4-
nitroindole, such that the indole moiety of 4-nitroindole mapped onto the structure of benzimidazole. 
 
9. Synthesis and characterization of tryptophan derivatives 
9.1 General information for biocatalytic reactions  
Proton and carbon NMR spectra were recorded either on a Bruker 400 MHz (100 MHz) spectrometer equipped 
with a cryogenic probe, or on a Varian 500 MHz (125 MHz) spectrometer. Fluorine NMR spectra were recorded on 
a Varian 500 MHz (400 MHz) spectrometer. Proton chemical shifts are reported in ppm (δ) relative to 
tetramethylsilane and calibrated using the residual solvent resonance (D2O, δ 4.79 ppm, unless specified otherwise). 
Data are reported as follows: chemical shift (multiplicity [singlet (s), doublet (d), doublet of doublets (dd), doublet 
of doublets of doublets (ddd), triplet (t), triplet of doubles (td), multiplet (m)], coupling constants [Hz], integration). 
Carbon NMR spectra were recorded with complete proton decoupling. Carbon chemical shifts are reported in ppm 
relative to tetramethylsilane and calibrated using the residual solvent proton resonance as an absolute reference, 
unless specified otherwise. All NMR spectra were recorded at ambient temperature (about 25 °C). Preparative 
reversed-phase chromatography was performed on a Biotage Isolera One purification system, using C-18 silica as 
the stationary phase, with methanol as the strong solvent and water (0.1% HCl by weight) as the weak solvent. The 
gradient of the eluent (Ñ) is given as % strong solvent/column volume (CV). High-resolution mass spectrometry 
(HRMS) was conducted with an Agilent 6200 TOF, with samples ionized by electrospray ionization (ESI), or a 
JMS-600H (JEOL) instrument, with samples ionized by fast atom bombardment (FAB). All starting materials were 
purchased from commercial sources and used without further purification. Liquid chromatography/mass 
spectrometry (LCMS) was performed on an Agilent 1290 UPLC-LCMS equipped with a 2.1 × 50 mm C-18 silica 
column, using acetonitrile as the strong solvent and 0.1% (v/v) acetic acid/water as the weak solvent. The optical 
purity of the products was determined by derivatization with N-(5-fluoro-2,4-dinitrophenyl)alanamide (FDNP-
alanamide)12 as described below.  
 
9.2 Screening catalyst panel against substrates 
Reactions used the procedure in Section 8.8. Product formation was approximated using HPLC by comparing the 
integration of product and substrate peaks at 277 nm. Catalyst loadings for each substrate are indicated in Table 3 of 
the manuscript. 
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Table S1. HPLC yields of tryptophan analogs with the catalyst panel 
Substitution Pf5G8 Pf2A6 Tm2F3 Tm2F3 I184F Pf0A9 Pf0A9 E104G
4-fluoro 88% 97% 100% 83% 99% 38%
4-bromo 57% 29% 69% 40% 30% 0%
4-cyano 11% 0% 10% 20% 0% 8%
5-cyano 30% 3% 81% 69% 8% 3%
5-aminocarbonyl 55% 0% 79% 79% 64% 0%
5-borono 31% 0% 41% 31% 44% 0%
5-iodo 12% 29% 14% 27% 60% 13%
5-trifluoromethyl 0% 30% 0% 0% 0% 0%
6-chloro 100% 53% 100% 100% 100% 47%
6-bromo 100% 28% 100% 100% 100% 38%
6-cyano 21% 14% 6% 5% 100% 73%
6-borono 3% 0% 0% 2% 63% 0%
7-cyano 68% 100% 100% 79% 92% 79%
7-chloro 56% 100% 83% 80% 100% 80%
7-bromo 63% 61% 62% 63% 62% 62%
7-iodo 87% 91% 90% 63% 100% 58%
5,6-dichloro 100% 11% 73% 55% 83% 48%
5-bromo-7-fluoro 70% 9% 89% 91% 81% 83%
5-chloro-7-iodo 8% 4% 20% 11% 16% 19%  
 
9.3 Preparative reactions for product characterization 
General procedure: the indole analog (100 µmol) and Ser (110 µmol) were added to a 40-mL reaction vial, 
followed by DMSO (500 µL). PLP (5 equiv with respect to enzyme) was added as an aqueous solution (1.5 mM), 
then followed by enough potassium phosphate buffer (200 mM, pH 8) to make the final volume (with enzyme) 10 
mL. The vial was sealed, then placed in a water bath that had been equilibrated to 75 °C. After 1 min, the enzyme 
was added. The reaction was kept at 75 °C. After 12 hours, the reaction mixture was frozen at –78 °C, then the water 
was removed by lyophilization. The residual solid was washed twice as follows to remove the DMSO: toluene (6 
mL) was added, then the suspension was heated to 75 °C. After 2 minutes, the suspension was cooled in ice, then the 
toluene was removed.  
The residual solid was suspended in 1:1 CH3CN/1 M aq. HCl, then the volume was reduced in vacuo. This 
process was repeated once more. Once the organic solvent had been completely removed, the residual aqueous 
component was loaded onto a C-18 column (12 g) that had been equilibrated to 1% methanol/water (0.1% HCl by 
mass). The column was washed with 2 column volumes (CV) of this solvent mixture to remove salts and trace 
DMSO. Finally, the product was eluted with a gradient from 1% to 100% methanol over 10 CV. The fractions 
containing product were combined, then the organic solvent was removed in vacuo. The residual water was frozen 
and removed by lyophilization. The products were obtained as the hydrochloride salts.  
 
9.4 Gram-scale preparation of 4-nitrotryptophan 
The enzyme Pf2A6 was prepared in a 1-L TBamp expression culture according to the procedure described in 
Section 7.1. For lysis, the cell pellet (10.3 grams) was suspended in 41 mL of 50-mM potassium phosphate buffer 
(pH 8) that contained 2.18 mg PLP, 41.2 mg HEWL, and 4.12 mg DNase. BugBuster (4.12 mL, 10× concentration) 
was added, and then the suspension was shaken at 230 RPM and 37 °C. After 15 minutes, the suspension was 
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subjected to centrifugation at 4,500×g and 4 °C (5 minutes), and then immersed in a water bath at 75 °C. After 30 
minutes, the suspension was cooled in ice, then subjected to centrifugation at 15,000×g and 4 °C (15 minutes).  
In a 500-mL Erlenmeyer flask, 4-nitroindole (973 mg, 6.00 mmol) and serine (694 mg, 6.60 mmol) were 
suspended in DMSO (6 mL) and 200-mM potassium phosphate buffer (84 mL, pH 8). Heat-treated lysate (30 mL) 
was added, then the reaction mixture was immersed in a water bath that was pre-heated to 75 °C. After 24 hours, the 
reaction mixture was cooled in ice, whereupon most of the 4-nitrotryptophan precipitated. The precipitate was 
collected by filtration, then washed with water and ethyl acetate. To remove insoluble impurities, such as 
precipitated protein, the product was dissolved in 1:1 1 M aq. HCl/CH3CN, then filtered again. The filtrate was 
concentrated in vacuo to afford 4-nitrotryptophan as the hydrochloride salt (yellow solid, 1.3 g, 73% yield).  
 
9.5 Determination of optical purity  
FDNP-alanamide was used as a solution in acetone (33 mM). In a 2-mL vial, the amino acid (0.50 µmol) was 
dissolved in 1 M aq. NaHCO3 (100 µL). FDNP-alanamide (10 µL, .33 µmol) was added, then the vial was placed in 
an incubator at 37 °C and shaken at 230 RPM. After 2 h, the reaction mixture was allowed to cool to room 
temperature, then diluted with 1:1 CH3CN/1 M aq. HCl (600 µL). The resulting solution was analyzed directly by 
LCMS (5% to 95% acetonitrile, monitored using the total ion count filtered for the expected mass). Each amino acid 
was derivatized with both racemic and enantiopure FDNP-alanamide for comparison. Absolute stereochemistry was 
inferred by analogy to L-tryptophan. All products were >99% ee, unless otherwise specified. 
 
9.6 Characterization of Trp analogs 
All compounds were characterized as the hydrochloride salt unless otherwise specified. 
4-nitrotryptophan (Table 3, entry 1). The 1H NMR was taken in a mixture of 1-M aq. HCl and 
CD3CN, with suppression of the H2O peak, and referenced to the residual acetonitrile peak (1.94 
ppm). The 13C NMR was taken in a mixture of DMSO-d6 and 20% DCl/D2O, and referenced to 
the residual DMSO peak (39.52 ppm). 1H NMR (400 MHz) δ 7.95 (dd, J = 8.0, 0.9 Hz, 1H), 7.83 
(dd, J = 8.0, 0.9 Hz, 1H), 7.51 (s, 1H), 7.26 (t, J = 8.0 Hz, 1H), 4.10 (dd, J = 9.4, 5.4 Hz, 1H), 3.48 (ABX, JAX = 9.3 
Hz, JBX = 5.4 Hz, JAB = 14.9 Hz, νAB = 183.8 Hz, 2H). 13C NMR (100 MHz) δ 172.2, 143.4, 141.0, 133.3, 122.8, 
121.3, 120.4, 120.1, 108.1, 55.9, 30.3. HRMS (ESI) (m/z) for [M+H]+ C11H12N3O4 requires 250.0822, observed 
250.0818. 
 
4-fluorotryptophan (Table 3, entry 2). 1H NMR (400 MHz, D2O) δ 7.27 (dd, J = 8.2, 0.7 Hz, 
1H), 7.21 (s, 1H), 7.14 (td, J = 8.0, 5.2 Hz, 1H), 6.81 (ddd, J = 11.7, 7.8, 0.7 Hz, 1H), 4.29 (dd, J 
= 8.4, 5.3 Hz, 1H), 3.43 (ABX, JAX = 8.4 Hz, JBX = 5.3 Hz, JAB = 15.1 Hz, νAB = 102.9 Hz, 2H).   
13C NMR (100 MHz, D2O) δ 172.0, 156.5 (d, JC–F = 242.5 Hz), 139.3 (d, JC–F = 11.6 Hz), 125.6, 
122.7 (d, JC–F = 8.0 Hz), 115.1 (d, JC–F = 20.0 Hz), 108.2 (d, JC–F = 3.5 Hz), 105.0 (d, JC–F = 2.5 Hz), 104.3 (d, JC–F = 
19.2 Hz), 54.3 (d, JC–F = 2.6 Hz), 27.1. HRMS (ESI) (m/z) for [M+H]+ C11H12FN2O2 requires 223.0877, observed 
223.0880. 
 
4-bromotryptophan (Table 3, entry 3). 1H NMR (400 MHz, D2O) δ 7.45 (dd, J = 8.2, 0.8 Hz, 
1H), 7.30 (dd, J = 7.6, 0.9 Hz, 1H), 7.28 (s, 1H), 7.06 (t, J = 7.9 Hz, 1H), 4.42 (dd, J = 9.9, 5.4 
Hz, 1H), 3.51 (ABX, JAX = 9.9 Hz, JBX = 5.4 Hz, JAB = 15.0 Hz, νAB = 266.9 Hz, 2H). 13C NMR 
(100 MHz, D2O) δ 171.9, 137.9, 127.4, 124.3, 123.7, 123.1, 112.6, 111.6, 107.3, 54.8, 26.9. 
HRMS (ESI) (m/z) for [M+H]+ C11H12BrN2O2 requires 283.0077, observed 283.0073. 
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4-cyanotryptophan (Table 3, entry 4). The 1H and 13C NMR spectra were taken in a mixture of 
DMSO-d6 and 20% DCl/D2O, and referenced to the residual DMSO peak (2.50 ppm and 39.52 
ppm for proton and carbon, respectively). 1H NMR (400 MHz) δ 7.55 (d, J = 8.3 Hz, 1H), 7.30 
(s, 2H), 7.29 (d, J = 7.7 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 4.03 (dd, J = 8.7, 6.2 Hz, 1H), 3.29 
(ABX, JAX = 8.8 Hz, JBX = 6.2 Hz, JAB = 15.3 Hz, νAB = 89.2 Hz, 2H). 13C NMR (100 MHz) δ 172.2, 138.4, 130.9, 
128.7, 127.8, 123.9, 121.7, 119.8, 108.4, 101.7, 55.5, 27.6. HRMS (ESI) (m/z) for [M+H]+ C12H12N3O2 requires 
230.0924, observed 230.0922. Enantiopurity 88% ee. 
 
5-nitrotryptophan (Table 3, entry 6). 1H NMR (400 MHz, D2O) δ 8.27 (d, J = 2.1 Hz, 1H), 
7.82 (dd, J = 9.1, 2.2 Hz, 1H), 7.31 (s, 1H), 7.31 (d, J = 9.0 Hz, 2H), 4.27 (dd, J = 6.8, 5.6 Hz, 
1H), 3.32 (ABX, JAX = 6.8 Hz, JBX = 5.6 Hz, JAB = 15.5 Hz, νAB = 21.6 Hz, 2H). 13C NMR (100 
MHz, D2O) δ 172.0, 140.4, 139.6, 128.4, 125.7, 117.3, 115.7, 111.7, 109.2, 53.3, 25.5. HRMS 
(FAB) (m/z) for [M+H]+ C11H12N3O4 requires 250.0828, observed 250.0831. Enantiopurity 
95% ee. 
 
5-cyanotryptophan (Table 3, entry 7). 1H NMR (500 MHz, D2O) δ 7.91 (dd, J = 1.6, 0.7 Hz, 
1H), 7.46 (dd, J = 8.5, 0.7 Hz, 1H), 7.38 (dd, J = 8.5, 1.5 Hz, 1H), 7.34 (s, 1H), 4.26 (dd, J = 7.0, 
5.4 Hz, 1H), 3.37 (ABXY, JAX = 7.0 Hz, JAY = 0.7 Hz, JBX = 5.5 Hz, JBY = 0.8 Hz, JAB = 15.5 
Hz, νAB = 27.8 Hz, 2H). 13C NMR (125 MHz, D2O) δ 172.1, 138.2, 127.4, 126.2, 124.8, 124.3, 
121.7, 112.6, 107.5, 100.7, 53.4, 25.5. HRMS (ESI) (m/z) for [M+H]+ C12H12N3O2 requires 
230.0924, observed 230.0921. Enantiopurity 90% ee. 
 
5-aminocarbonyltryptophan (Table 3, entry 8). 1H NMR (400 MHz, D2O) δ 7.95 (dd, J = 
1.8, 0.7 Hz, 1H), 7.51 (dd, J = 8.6, 1.8 Hz, 1H), 7.39 (dd, J = 8.6, 0.7 Hz, 1H), 7.27 (s, 1H), 
4.27 (dd, J = 6.9, 5.4 Hz, 1H), 3.34 (ABX, JAX = 7.1 Hz, JBX = 5.6 Hz, JAB = 15.6 Hz, νAB = 
23.3 Hz, 2H). 13C NMR (100 MHz, D2O) δ 174.0, 172.7, 138.6, 126.9, 126.3, 123.6, 121.2, 
118.9, 111.9, 108.0, 53.9, 25.8. HRMS (ESI) (m/z) for [M+H]+ C12H14N3O3 requires 
248.1030, observed 248.1031. 
 
5-boronotryptophan (Table 3, entry 9). For this product, HCl was omitted from all parts of 
the procedure and purification. The compound was isolated as the free base and contained 
DMSO (~4% by mass). 1H NMR (400 MHz, D2O) δ 8.02 (t, J = 1.1 Hz, 1H), 7.53 (dd, J = 
8.2, 1.2 Hz, 1H), 7.46 (dd, J = 8.2, 0.8 Hz, 1H), 7.23 (s, 1H), 3.86 (dd, J = 7.7, 5.0 Hz, 1H), 
3.26 (ABXY, JAX = 7.8 Hz, JAY = 0.7 Hz, JBX = 5.0 Hz, JBY = 0.9 Hz, JAB = 15.0 Hz, νAB = 
71.9 Hz, 2H). 13C NMR (100 MHz, D2O) δ 177.3, 137.5, 126.8, 126.6, 124.8, 124.1, 111.3, 108.8, 55.5, 27.6. 
HRMS (ESI) (m/z) for [M+H]+ C11H14BN2O4 requires 249.1041, observed 249.1048. 
 
5-iodotryptophan (Table 3, entry 10). 1H NMR (400 MHz, D2O) δ 7.97 (d, J = 1.3 Hz, 2H), 
7.46 (dd, J = 8.6, 1.6 Hz, 1H), 7.26 (dd, J = 8.6, 0.6 Hz, 1H), 7.22 (s, 1H), 4.25 (dd, J = 7.3, 5.3 
Hz, 1H), 3.34 (ABX, JAX = 7.4 Hz, JBX = 5.3 Hz, JAB = 15.4 Hz, νAB = 36.7 Hz, 2H). 13C NMR 
(100 MHz, D2O) δ 172.2, 135.4, 130.2, 129.1, 127.0, 126.1, 114.0, 105.9, 82.2, 53.5, 25.8. 
HRMS (ESI) (m/z) for [M+H]+ C11H12IN2O2 requires 330.9938, observed 330.9937. 
 
5-trifluoromethyltryptophan (Table 3, entry 11). The 1H and 13C NMR spectra were taken 
in DMSO-d6 and referenced to the residual DMSO peak (2.50 ppm and 39.52 ppm for proton 
and carbon, respectively). 1H NMR (400 MHz, DMSO-d6) δ 7.97 (s, 1H), 7.81 (d, J = 8.6 Hz, 
1H), 7.59 (d, J = 3.3 Hz, 1H), 7.46 (dd, J = 8.8, 1.8 Hz, 1H), 6.67 (dd, J = 3.2, 0.8 Hz, 1H), 
4.74 (d, J = 5.8 Hz, 2H), 4.29 (t, J = 5.8 Hz, 1H). 13C NMR (100 MHz, DMSO-d6) δ 169.0, 137.7, 131.6, 127.8, 
125.5 (q, JC–F = 271.4 Hz), 120.4 (q, JC–F = 31.1 Hz), 118.1 (q, JC–F = 4.3 Hz), 117.8 (q, JC–F = 3.6 Hz), 110.9, 103.0, 
52.6, 45.7. 19F NMR (400 MHz, DMSO-d6) 58.19. HRMS (ESI) (m/z) for [M+H]+ C12H12F3N2O2 requires 
273.0845, observed 273.0849. Enantiopurity 93% ee. 
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6-nitrotryptophan (Table 3, entry 12). 1H NMR (400 MHz, D2O) δ 8.11 (d, J = 2.1 Hz, 
1H), 7.77 (dd, J = 8.9, 2.1 Hz, 1H), 7.51 (d, J = 8.9 Hz, 1H), 7.49 (s, 1H), 4.26 (t, J = 6.2 Hz, 
1H), 3.36 (ABX, JAX = 7.0 Hz, JBX = 5.7 Hz, JAB = 15.5 Hz, νAB = 23.6 Hz, 2H). 13C NMR 
(100 MHz, D2O) δ 172.1, 142.1, 134.4, 131.6, 131.4, 117.9, 114.5, 108.8, 107.8, 53.5, 25.5. 
HRMS (ESI) (m/z) for [M+H]+ C11H12N3O4 requires 250.0822, observed 250.0818. Enantiopurity 96% ee. 
 
6-chlorotryptophan (Table 3, entry 13). 1H NMR (400 MHz, D2O) δ 7.54 (d, J = 8.5 Hz, 
1H), 7.47 (d, J = 1.8 Hz, 1H), 7.25 (s, 1H), 7.10 (dd, J = 8.5, 1.9 Hz, 1H), 4.27 (dd, J = 7.1, 
5.4 Hz, 1H), 3.38 (ABX, JAX = 7.2 Hz, JBX = 5.4 Hz, JAB = 15.4 Hz, νAB = 31.0 Hz, 2H). 13C 
NMR (100 MHz, D2O) δ 172.3, 136.8, 127.5, 126.1, 125.3, 120.0, 119.3, 111.7, 106.8, 53.6, 
25.8. HRMS (ESI) (m/z) for [M+H]+ C11H12ClN2O2 requires 239.0582, observed 239.0575.  
 
6-bromotryptophan (Table 3, entry 14). 1H NMR (400 MHz, D2O) δ 7.60 (dd, J = 1.7, 0.6 
Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 7.21 (s, 1H), 7.20 (dd, J = 8.5, 1.7 Hz, 1H), 4.26 (dd, J = 
7.1, 5.3 Hz, 1H), 3.36 (ABXY, JAX = 7.1 Hz, JAY = 0.7 Hz, JBX = 5.4 Hz, JBY = 0.8 Hz, JAB = 
15.4 Hz, νAB = 30.2 Hz, 2H). 13C NMR (100 MHz, D2O) δ 172.3, 137.1, 126.0, 125.5, 122.5, 
119.7, 115.0, 114.6, 106.8, 53.6, 25.8. HRMS (ESI) (m/z) for [M+H]+ C11H12BrN2O2 requires 283.0077, observed 
283.0071. 
 
6-cyanotryptophan (Table 3, entry 15). 1H NMR (500 MHz, D2O) δ 7.73 (dd, J = 1.4, 0.7 
Hz, 1H), 7.61 (dd, J = 8.3, 0.7 Hz, 1H), 7.44 (s, 1H), 7.28 (dd, J = 8.3, 1.4 Hz, 1H), 4.27 (dd, J 
= 7.0, 5.5 Hz, 1H), 3.39 (ABXY, JAX = 7.0 Hz, JAY = 0.7 Hz, JBX = 5.6 Hz, JBY = 0.8 Hz, JAB 
= 15.5 Hz, νAB = 28.6 Hz, 2H). 13C NMR (100 MHz, D2O) δ 172.1, 153.0, 131.7, 126.9, 
126.2, 112.9, 111.9, 106.1, 100.5, 56.0, 53.3, 25.7. HRMS (ESI) (m/z) for [M+H]+ C12H12N3O2 requires 230.0924, 
observed 230.0925. 
 
6-boronotryptophan (Table 3, entry 16). The isolated compound contained DMSO (<1% 
by mass) and tryptophan (8% by mass). 1H NMR (500 MHz, D2O) δ 7.92 (t, J = 1.0 Hz, 
1H), 7.71 (dd, J = 8.1, 0.8 Hz, 1H), 7.53 (dd, J = 8.1, 1.1 Hz, 1H), 7.42 (s, 1H), 4.39 (dd, J 
= 7.2, 5.3 Hz, 1H), 3.50 (ABXY, JAX = 7.0 Hz, JBX = 5.4 Hz, JBY = 0.8 Hz, JAB = 15.5 Hz, 
νAB = 19.0 Hz, 2H). 13C NMR (125 MHz, D2O) δ 172.1, 136.2, 128.7, 127.0, 124.2, 117.9, 117.8, 106.5, 53.5, 25.8. 
HRMS (ESI) (m/z) for [M+H]+ C11H14BN2O4 requires 249.1041, observed 249.1044. 
 
7-nitrotryptophan (Table 3, entry 17). 1H NMR (400 MHz, D2O) δ 8.03 (d, J = 8.1 Hz, 1H), 
7.94 (d, J = 7.8 Hz, 1H), 7.34 (s, 1H), 7.15 (t, J = 8.0 Hz, 1H), 4.25 (dd, J = 7.1, 5.4 Hz, 1H), 
3.41 (ABX, JAX = 7.2 Hz, JBX = 5.4 Hz, JAB = 15.5 Hz, νAB = 30.8 Hz, 2H). 13C NMR (100 
MHz, D2O) δ 172.1, 132.0, 130.5, 128.8, 127.3, 127.0, 119.6, 118.9, 108.6, 53.5, 25.4. HRMS 
(ESI) (m/z) for [M+H]+ C11H12N3O4 requires 250.0822, observed 250.0820. 
 
7-cyanotryptophan (Table 3, entry 18). 1H NMR (400 MHz, D2O) δ 7.79 (dd, J = 8.1, 1.0 
Hz, 1H), 7.47 (dd, J = 7.5, 1.0 Hz, 1H), 7.28 (s, 1H), 7.11 (dd, J = 8.0, 7.5 Hz, 1H), 4.27 (dd, J 
= 7.0, 5.5 Hz, 1H), 3.37 (ABXY, JAX = 7.1 Hz, JAY = 0.7 Hz, JBX = 5.6 Hz, JBY = 0.8 Hz, JAB = 
15.4 Hz, νAB = 26.4 Hz, 2H). 13C NMR (100 MHz, D2O) δ 172.2, 136.1, 127.4, 127.3, 126.6, 
124.1, 119.3, 117.9, 108.0, 93.5, 53.5, 25.6. HRMS (ESI) (m/z) for [M+H]+ C12H12N3O2 requires 230.0924, 
observed 230.0920. Enantiopurity: 97% ee. 
 
7-chlorotryptophan (Table 3, entry 19). 1H NMR (400 MHz, D2O) δ 7.56 (d, J = 7.8 Hz, 
1H), 7.32 (s, 1H), 7.26 (d, J = 7.5 Hz, 1H), 7.10 (t, J = 7.8 Hz, 1H), 4.28 (dd, J = 7.1, 5.4 Hz, 
1H), 3.41 (ABX, JAX = 7.2 Hz, JBX = 5.4 Hz, JAB = 15.4 Hz, νAB = 33.8 Hz, 2H). 13C NMR 
(100 MHz, D2O) δ 172.2, 136.1, 127.4, 127.3, 126.6, 124.1, 119.3, 117.9, 108.0, 93.5, 53.5, 
25.6. HRMS (ESI) (m/z) for [M+H]+ C11H12ClN2O2 requires 239.0582, observed 239.0577. 
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7-iodotryptophan (Table 3, entry 20). 1H NMR (400 MHz, D2O) δ 7.63 (d, J = 7.7 Hz, 1H), 
7.32 (s, 1H), 6.93 (t, J = 7.7 Hz, 1H), 4.27 (dd, J = 7.3, 5.3 Hz, 1H), 3.38 (ABXY, JAX = 7.3 Hz, 
JAY = 0.7 Hz, JBX = 5.4 Hz, JBY = 0.8 Hz, JAB = 15.4 Hz, νAB = 36.5 Hz, 2H). 13C NMR (100 
MHz, D2O) δ 172.3, 138.2, 131.1, 126.8, 125.7, 121.2, 118.5, 108.2, 76.0, 53.6, 26.1. HRMS 
(ESI) (m/z) for [M+H]+ C11H12IN2O2 requires 330.9938, observed 330.9925. 
 
7-bromotryptophan (Table 3, entry 21). 1H NMR (400 MHz, D2O) δ 7.61 (dd, J = 8.0, 0.9 
Hz, 1H), 7.42 (dd, J = 7.6, 0.8 Hz, 1H), 7.34 (s, 1H), 7.05 (t, J = 7.8 Hz, 1H), 4.31 (dd, J = 7.1, 
5.4 Hz, 1H), 3.42 (ABX, JAX = 7.1 Hz, JBX = 5.4 Hz, JAB = 15.4 Hz, νAB = 31.4 Hz, 2H). 13C 
NMR (100 MHz, D2O) δ 172.4, 134.9, 128.0, 125.9, 124.6, 120.8, 117.7, 108.0, 104.6, 53.6, 
26.0. HRMS (ESI) (m/z) for [M+H]+ C11H12BrN2O2 requires 283.0077, observed 283.0066. 
 
5,6-dichlorotryptophan (Table 3, entry 23). 1H NMR (400 MHz, D2O) δ 7.58 (s, 1H), 7.47 (s, 
1H), 7.23 (s, 1H), 4.22 (dd, J = 7.2, 5.4 Hz, 1H), 3.30 (ABX, JAX = 7.1 Hz, JBX = 5.1 Hz, JAB = 15.5 
Hz, νAB = 28.4 Hz, 2H). 13C NMR (100 MHz, D2O) δ 172.2, 135.0, 127.1, 126.3, 124.7, 122.4, 
118.9, 113.0, 106.3, 53.4, 25.7. HRMS (ESI) (m/z) for [M+H]+ C11H11Cl2N2O2 requires 
273.0192, observed 273.0188. 
 
5-bromo-7-fluorotryptophan (Table 3, entry 24). 1H NMR (500 MHz, D2O) δ 7.50 (d, J = 1.5 
Hz, 1H), 7.25 (s, 1H), 7.07 (dd, J = 10.6, 1.6 Hz, 1H), 4.23 (dd, J = 7.3, 5.3 Hz, 1H), 3.32 
(ABX, JAX = 7.3 Hz, JBX = 5.3 Hz, JAB = 15.4 Hz, νAB = 38.8 Hz, 2H). 13C NMR (125 MHz, 
D2O) δ 172.1, 148.9 (d, JC–F = 248.2 Hz), 147.9, 131.1 (d, JC–F = 6.4 Hz), 126.9, 123.4 (d, JC–F = 
13.6 Hz), 116.7, 110.6 (d, JC–F = 8.2 Hz), 110.2 (d, JC–F = 20.1 Hz), 107.1 (d, JC–F = 1.9 Hz), 53.4, 25.7. HRMS 
(ESI) (m/z) for [M+H]+ C11H11BrFN2O2 requires 300.9982, observed 300.9979. 
 
5-chloro-7-iodotryptophan (Table 3, entry 25). 1H NMR (500 MHz, D2O) δ 7.59–7.47 (m, 
2H), 7.28 (s, 1H), 4.20 (dd, J = 7.2, 5.3 Hz, 1H), 3.30 (ABXY, JAX = 7.3 Hz, JAY = 0.7 Hz, JBX = 
5.3 Hz, JBY = 0.8 Hz, JAB = 15.4 Hz, νAB = 39.3 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 
171.0, 136.9, 128.9, 128.1, 127.9, 123.9, 118.0, 108.6, 77.8, 52.7, 26.0. HRMS (ESI) (m/z) for 
[M+H]+ C11H11ClIN2O2 requires 364.9548, observed 364.9537. 
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